Participants
The study was carried out at the Regional MS Center of Cagliari (Sardinia, Italy) and at the Laboratory of Biomechanics and Industrial Ergonomics of the University of Cagliari (Cagliari, Italy). The participants were selected among PwMS considered eligible for using nabiximols based on their clinical history. Inclusion criteria were as follows: a diagnosis of MS according to the 2017 McDonald criteria [Immediately after the nabiximols prescription, PwMS were offered to enter the study. The baseline assessment (The study, which was conducted according to the World Medical Association Declaration of Helsinki principles, received formal approval by the ethics committee of ATS Sardegna (protocol number 198/2019/CE). All participants signed an informed consent agreeing to participate.